Knight Therapeutics Inc. announced that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Principal with Bain & Company where he served as a strategy consultant for 14 years. Additionally, Mr. Kadanoff was Vice President-Strategic Planning and Development at Reitmans.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.88 CAD | +0.17% | -2.00% | +13.29% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.29% | 434M | |
+18.88% | 81.33B | |
+14.11% | 9.14B | |
-14.14% | 4.89B | |
+43.39% | 4.61B | |
+18.90% | 4.36B | |
+7.93% | 2.26B | |
-28.40% | 2.15B | |
+15.93% | 2.1B | |
-43.17% | 1.78B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Appoints Jeffrey Kadanoff as New CFO